{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:17:10Z","timestamp":1771305430514,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.05.028","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:20:44Z","timestamp":1750868444000},"page":"1165-1173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiation Therapy in the Management of Muscle-invasive Bladder Cancer with Carcinoma in Situ: Still a No Go?"],"prefix":"10.1016","volume":"8","author":[{"given":"Constance","family":"Huck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9rane","family":"Achard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien Van","family":"Damme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.05.028_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.05.028_b0010","unstructured":"World Health Organization. GLOBOCAN 2020: cancer incidence and mortality worldwide. Lyon, France: International Agency for Research on Cancer; 2020. https:\/\/gco.iarc.fr\/."},{"key":"10.1016\/j.euo.2025.05.028_b0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0020","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdz296","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees","volume":"30","author":"Horwich","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0025","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): bladder cancer version 7.2024. Plymouth Meeting, PA: NCCN; 2024."},{"key":"10.1016\/j.euo.2025.05.028_b0030","doi-asserted-by":"crossref","unstructured":"Gupta S, Hensley PJ, Li R, et al. Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.03.017.","DOI":"10.1016\/j.eururo.2025.03.017"},{"key":"10.1016\/j.euo.2025.05.028_b0035","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.028_b0045","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(85)91612-5","article-title":"Urothelial dysplasia concomitant with bladder tumours: a determinant for future new occurrences in patients treated by full-course radiotherapy","volume":"1","author":"Wolf","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.05.028_b0050","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0022-5347(17)47381-2","article-title":"Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival","volume":"134","author":"Shipley","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.05.028_b0055","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0022-5347(17)39122-X","article-title":"Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis","volume":"142","author":"Gospodarowicz","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.05.028_b0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.urolonc.2006.09.015","article-title":"Long-term outcome of radiation-based conservation therapy for invasive bladder cancer","volume":"25","author":"Chung","year":"2007","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0065","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital Experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.028_b0070","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","article-title":"Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy","volume":"80","author":"Zapatero","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.05.028_b0075","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"R\u00f6del","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0080","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1634\/theoncologist.2018-0280","article-title":"Long-term experience of chemoradiotherapy combined with deep regional hyperthermia for organ preservation in high-risk bladder cancer (Ta, Tis, T1, T2)","volume":"24","author":"Merten","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2025.05.028_b0085","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.1991.9.9.1533","article-title":"Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy","volume":"9","author":"Fung","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0090","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.urolonc.2012.01.014","article-title":"Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients","volume":"31","author":"Koga","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.urology.2003.09.018","article-title":"Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution","volume":"63","author":"Peyromaure","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.05.028_b0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.critrevonc.2014.11.007","article-title":"A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)","volume":"94","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euo.2025.05.028_b0105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0110","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1002\/hed.26411","article-title":"Curative-intent radiotherapy for glottic carcinoma in situ","volume":"42","author":"Mendenhall","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.euo.2025.05.028_b0115","first-page":"572","article-title":"Treatment results of carcinoma in situ of the glottic larynx: 61 patients treated with radiotherapy","volume":"37","author":"Charbonneau","year":"2008","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.euo.2025.05.028_b0120","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.23.02510","article-title":"Bladder-preserving trimodality treatment for high-grade t1 bladder cancer: results from phase II Protocol NRG Oncology\/RTOG 0926","volume":"42","author":"Dahl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0125","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.euo.2024.03.008","article-title":"Radiotherapy combined with a radiosensitizer for bacillus Calmette-Gu\u00e9rin\u2013unresponsive non\u2013muscle-invasive carcinoma in situ bladder cancer: an open-label, single-arm, multicenter, phase 2 European Organisation for Research and Treatment of Cancer trial","volume":"7","author":"Achard","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin\u2013exposed high-risk non\u2013muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.028_b0135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.05.028_b0140","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0145","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.111","article-title":"LBA105\u2003Results from SunRISe-1 in patients (Pts) with bacillus Calmette\u2013Gu\u00e9rin (BCG)-unresponsive high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.05.028_b0150","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with bacillus Calmette-Gu\u00e9rin (BCG) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"Oncoimmunology"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:27:07Z","timestamp":1758079627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001737"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.028","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy in the Management of Muscle-invasive Bladder Cancer with Carcinoma in Situ: Still a No Go?","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}